Onkologie 2020: 14(Suppl.A): 17-20 | DOI: 10.36290/xon.2020.030

Serious complications in a patient with generalized non-small cell lung cancer treated with pembrolizumab

Jan Stejskal
Oddělení klinické a radiační onkologie, Nemocnice Pardubice

Treatment with pembrolizumab was initiated in a patient with generalized NSCLC with a PD-L1 expression of 90 %. After four months of treatment, he suddenly developed toxicity (irAEs) - exacerbation of grade 3 ulcerative colitis and other serious complications which required cardiopulmonary resuscitation. The life-threatening condition was managed successfully and the patient continues to receive immunotherapy.

Keywords: NSCLC, PD-L1, immunotherapy, irAEs, pembrolizumab.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stejskal J. Serious complications in a patient with generalized non-small cell lung cancer treated with pembrolizumab. Onkologie. 2020;14(Suppl.A / Onkologické kazuistiky 1):17-20. doi: 10.36290/xon.2020.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Felip E, Hellman M, Hui R, et al. 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: results from KEYNOTE-001. Proc Am Soc Clin Oncol. 2018; 36 (abstr 9030). Go to original source... Go to PubMed...
    2. Brahmer J, Rodriguez-Abreu D, Robinson A, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017; 18: 1600-1609. Go to original source... Go to PubMed...
    3. Mok T, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled phase 3 trial. Lancet. 2019; (published online April 4.) S0140-6736(18)32409-7.
    4. Puyuan X, Di M, Qiang W, et al. Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study. Chin J Cancer Res. 2019 Jun; 31(3): 481-488. Go to original source... Go to PubMed...
    5. Topalian S, Hodi F, Brahmer J, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol. 2019 Jul 25: e192187. Go to original source... Go to PubMed...
    6. Ramalingam S, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2019;DOI:10.1056/NEJMoa1913662. Go to original source... Go to PubMed...
    7. Miller V, Hirsh V, Cadranel J, et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). In: Presented at European Society of Medical Oncology (ESMO) Congress. 2010 [abstractact LBA1].
    8. Wang C, Li Y, Ke L, et al. The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. J Cancer 2019; 10(4): 885-892. Go to original source...
    9. Brahmer J, Drake C, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19): 3167-75. Go to original source... Go to PubMed...
    10. Mahoney K, Atkins M. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 2014; 28(Suppl. 3): 39-48. Go to PubMed...
    11. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc) 2015; 51(1): 7-20. Go to original source... Go to PubMed...
    12. Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264. Go to original source... Go to PubMed...
    13. Dunn G, Bruce A, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998. Go to original source... Go to PubMed...
    14. Herbst R, Baas P, Kim D, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387: 1540-1550. Go to original source... Go to PubMed...
    15. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single agent chemotherapy. JAMA Oncol. 2018; 4: 1543-1552. Go to original source... Go to PubMed...
    16. Reck M, Rodriguez-Abreu D, Robinson A, et al. Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer. N Engl J Med. 2016; 375: 1823-1833. Go to original source... Go to PubMed...
    17. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer. N Engl J Med. 2018; 378: 2078-2092. Go to original source... Go to PubMed...
    18. Yeonghee E, In Young K, Jong-Mu S, et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Scientific Reports volume 9, Article number: 2019; 14039. Go to original source... Go to PubMed...
    19. Naidoo J, Page D, Li B, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology, Volume 26, Issue 12, December 2015: 2375-2391. Go to original source... Go to PubMed...
    20. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf
    21. Di Giacomo A, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507. Go to original source... Go to PubMed...
    22. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_cs.pdf
    23. Postow M. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 35: 76-83. Go to original source... Go to PubMed...
    24. Weber J, Yang J, Atkins M, et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015; 33: 2092-2099. Go to original source... Go to PubMed...
    25. Schwartz R, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 2002; 16: 11-20.
    26. Momtaz P, Park V, Panageas K, et al. Safety of infusing ipilimumab over 30 minutes. J Clin Oncol 2015 June 29 [epub ahead of print], doi: 10.1200/JCO.2015.61.0030. Go to original source... Go to PubMed...
    27. Robert C, Schachter J, Long G, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.